Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.

Keefer MC, Frey SE, Elizaga M, Metch B, De Rosa SC, Barroso PF, Tomaras G, Cardinali M, Goepfert P, Kalichman A, Philippon V, McElrath MJ, Jin X, Ferrari G, Defawe OD, Mazzara GP, Montefiori D, Pensiero M, Panicali DL, Corey L; NIAID HIV Vaccine Trials Network.

Vaccine. 2011 Feb 24;29(10):1948-58. doi: 10.1016/j.vaccine.2010.12.104. Epub 2011 Jan 7.

2.

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR.

J Clin Oncol. 2010 Mar 1;28(7):1099-105. doi: 10.1200/JCO.2009.25.0597. Epub 2010 Jan 25.

3.

A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers.

Ramanathan VD, Kumar M, Mahalingam J, Sathyamoorthy P, Narayanan PR, Solomon S, Panicali D, Chakrabarty S, Cox J, Sayeed E, Ackland J, Verlinde C, Vooijs D, Loughran K, Barin B, Lombardo A, Gilmour J, Stevens G, Smith MS, Tarragona-Fiol T, Hayes P, Kochhar S, Excler JL, Fast P.

AIDS Res Hum Retroviruses. 2009 Nov;25(11):1107-16. doi: 10.1089/aid.2009.0096.

PMID:
19943789
4.

Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy.

Greenough TC, Cunningham CK, Muresan P, McManus M, Persaud D, Fenton T, Barker P, Gaur A, Panicali D, Sullivan JL, Luzuriaga K; Pediatric AIDS Clinical Trials Group P1059 Team.

Vaccine. 2008 Dec 9;26(52):6883-93. doi: 10.1016/j.vaccine.2008.09.084. Epub 2008 Oct 20.

5.

Therapeutic vaccination against murine lymphoma by intratumoral injection of recombinant fowlpox virus encoding CD40 ligand.

Liu A, Guardino A, Chinsangaram L, Goldstein MJ, Panicali D, Levy R.

Cancer Res. 2007 Jul 15;67(14):7037-44.

6.

Heterologous prime/boost immunization of rhesus monkeys by using diverse poxvirus vectors.

Santra S, Sun Y, Parvani JG, Philippon V, Wyand MS, Manson K, Gomez-Yafal A, Mazzara G, Panicali D, Markham PD, Montefiori DC, Letvin NL.

J Virol. 2007 Aug;81(16):8563-70. Epub 2007 Jun 6.

7.

Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.

Jäger E, Karbach J, Gnjatic S, Neumann A, Bender A, Valmori D, Ayyoub M, Ritter E, Ritter G, Jäger D, Panicali D, Hoffman E, Pan L, Oettgen H, Old LJ, Knuth A.

Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14453-8. Epub 2006 Sep 19.

8.

Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma.

Lindsey KR, Gritz L, Sherry R, Abati A, Fetsch PA, Goldfeder LC, Gonzales MI, Zinnack KA, Rogers-Freezer L, Haworth L, Mavroukakis SA, White DE, Steinberg SM, Restifo NP, Panicali DL, Rosenberg SA, Topalian SL.

Clin Cancer Res. 2006 Apr 15;12(8):2526-37.

9.

Preservation of functional virus-specific memory CD8+ T lymphocytes in vaccinated, simian human immunodeficiency virus-infected rhesus monkeys.

Acierno PM, Schmitz JE, Gorgone DA, Sun Y, Santra S, Seaman MS, Newberg MH, Mascola JR, Nabel GJ, Panicali D, Letvin NL.

J Immunol. 2006 May 1;176(9):5338-45.

10.

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.

Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, Beetham P, Tsang KY, Grosenbach DW, Feldman J, Steinberg SM, Jones E, Chen C, Marte J, Schlom J, Dahut W.

Clin Cancer Res. 2006 Feb 15;12(4):1260-9.

11.

Costimulatory molecules as adjuvants for immunotherapy.

Hodge JW, Greiner JW, Tsang KY, Sabzevari H, Kudo-Saito C, Grosenbach DW, Gulley JL, Arlen PM, Marshall JL, Panicali D, Schlom J.

Front Biosci. 2006 Jan 1;11:788-803. Review.

PMID:
16146771
12.

Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules.

Palena C, Foon KA, Panicali D, Yafal AG, Chinsangaram J, Hodge JW, Schlom J, Tsang KY.

Blood. 2005 Nov 15;106(10):3515-23. Epub 2005 Aug 4.

13.

Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma.

Kaufman HL, Deraffele G, Mitcham J, Moroziewicz D, Cohen SM, Hurst-Wicker KS, Cheung K, Lee DS, Divito J, Voulo M, Donovan J, Dolan K, Manson K, Panicali D, Wang E, Hörig H, Marincola FM.

J Clin Invest. 2005 Jul;115(7):1903-12. Epub 2005 Jun 2.

14.

Role of genes that modulate host immune responses in the immunogenicity and pathogenicity of vaccinia virus.

Jackson SS, Ilyinskii P, Philippon V, Gritz L, Yafal AG, Zinnack K, Beaudry KR, Manson KH, Lifton MA, Kuroda MJ, Letvin NL, Mazzara GP, Panicali DL.

J Virol. 2005 May;79(10):6554-9.

15.

Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.

Morse MA, Clay TM, Hobeika AC, Osada T, Khan S, Chui S, Niedzwiecki D, Panicali D, Schlom J, Lyerly HK.

Clin Cancer Res. 2005 Apr 15;11(8):3017-24.

16.

Dysfunction of simian immunodeficiency virus/simian human immunodeficiency virus-induced IL-2 expression by central memory CD4+ T lymphocytes.

Sun Y, Schmitz JE, Acierno PM, Santra S, Subbramanian RA, Barouch DH, Gorgone DA, Lifton MA, Beaudry KR, Manson K, Philippon V, Xu L, Maecker HT, Mascola JR, Panicali D, Nabel GJ, Letvin NL.

J Immunol. 2005 Apr 15;174(8):4753-60.

17.

Vaccine-elicited memory cytotoxic T lymphocytes contribute to Mamu-A*01-associated control of simian/human immunodeficiency virus 89.6P replication in rhesus monkeys.

Seaman MS, Santra S, Newberg MH, Philippon V, Manson K, Xu L, Gelman RS, Panicali D, Mascola JR, Nabel GJ, Letvin NL.

J Virol. 2005 Apr;79(8):4580-8.

18.

Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.

Tsang KY, Palena C, Yokokawa J, Arlen PM, Gulley JL, Mazzara GP, Gritz L, Yafal AG, Ogueta S, Greenhalgh P, Manson K, Panicali D, Schlom J.

Clin Cancer Res. 2005 Feb 15;11(4):1597-607.

19.

Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.

Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang KY, Slack R, Hodge JW, Doren S, Grosenbach DW, Hwang J, Fox E, Odogwu L, Park S, Panicali D, Schlom J.

J Clin Oncol. 2005 Feb 1;23(4):720-31. Epub 2004 Dec 21.

PMID:
15613691
20.

Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses.

Santra S, Barouch DH, Korioth-Schmitz B, Lord CI, Krivulka GR, Yu F, Beddall MH, Gorgone DA, Lifton MA, Miura A, Philippon V, Manson K, Markham PD, Parrish J, Kuroda MJ, Schmitz JE, Gelman RS, Shiver JW, Montefiori DC, Panicali D, Letvin NL.

Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):11088-93. Epub 2004 Jul 16.

21.

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.

Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ, Truitt DM, Sumida SM, Kishko MG, Arthur JC, Korioth-Schmitz B, Newberg MH, Gorgone DA, Lifton MA, Panicali DL, Nabel GJ, Letvin NL, Goudsmit J.

J Immunol. 2004 May 15;172(10):6290-7.

22.

Avipox-based simian immunodeficiency virus (SIV) vaccines elicit a high frequency of SIV-specific CD4+ and CD8+ T-cell responses in vaccinia-experienced SIVmac251-infected macaques.

Nacsa J, Radaelli A, Edghill-Smith Y, Venzon D, Tsai WP, Morghen Cde G, Panicali D, Tartaglia J, Franchini G.

Vaccine. 2004 Jan 26;22(5-6):597-606.

PMID:
14741150
23.

Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.

Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Topalian SL, Sherry RM, Restifo NP, Wunderlich JR, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, Gritz L, Panicali DL, White DE.

Clin Cancer Res. 2003 Aug 1;9(8):2973-80.

24.

Prior DNA immunization enhances immune response to dominant and subdominant viral epitopes induced by a fowlpox-based SIVmac vaccine in long-term slow-progressor macaques infected with SIVmac251.

Radaelli A, Nacsa J, Tsai WP, Edghill-Smith Y, Zanotto C, Elli V, Venzon D, Tryniszewska E, Markham P, Mazzara GP, Panicali D, De Giuli Morghen C, Franchini G.

Virology. 2003 Jul 20;312(1):181-95.

25.

Clinical protocol. Intra-Lesional rF-B7.1 versus rF-TRICOM vaccine in the treatment of metastatic cancer.

Kaufman HL, Cheung K, Haskall Z, Horig H, Hesdorffer C, Panicali D, DeRaffele G, Spanknebel K.

Hum Gene Ther. 2003 May 20;14(8):803-27. No abstract available.

PMID:
12804142
26.

Evidence for immune-mediated reduction of viral replication in Macaca nemestrina mucosally immunized with inactivated SHIV(89.6).

Ambrose Z, Thompson J, Larsen K, Kuller L, Panicali DL, Clements JD, Agy M, Montefiori DC, Hu SL, Bosch ML.

Virology. 2003 Mar 30;308(1):178-90.

27.

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.

Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, Tsang K, Panicali D, Poole D, Schlom J, Michael Hamilton J.

Prostate. 2002 Oct 1;53(2):109-17.

PMID:
12242725
28.

A phase I trial of intralesional rV-Tricom vaccine in the treatment of malignant melanoma.

Kaufman HL, DeRaffele G, Divito J, Hörig H, Lee D, Panicali D, Voulo M.

Hum Gene Ther. 2001 Jul 20;12(11):1459-80. No abstract available.

PMID:
11485637
29.

Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells.

Zhu M, Terasawa H, Gulley J, Panicali D, Arlen P, Schlom J, Tsang KY.

Cancer Res. 2001 May 1;61(9):3725-34.

31.

Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL.

Chen JL, Dunbar PR, Gileadi U, Jäger E, Gnjatic S, Nagata Y, Stockert E, Panicali DL, Chen YT, Knuth A, Old LJ, Cerundolo V.

J Immunol. 2000 Jul 15;165(2):948-55.

32.

A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.

Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY, Panicali D, Schlom J, Kufe DW.

Clin Cancer Res. 2000 May;6(5):1632-8.

33.

A phase I trial of intra lesional RV-B7.1 vaccine in the treatment of malignant melanoma.

Kaufman HL, Conkright W, Divito J Jr, Hörig H, Kaleya R, Lee D, Mani S, Panicali D, Rajdev L, Ravikumar TS, Wise-Campbell S, Surhland MJ.

Hum Gene Ther. 2000 May 1;11(7):1065-82. No abstract available.

PMID:
10811235
34.

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations.

Robinson HL, Montefiori DC, Johnson RP, Manson KH, Kalish ML, Lifson JD, Rizvi TA, Lu S, Hu SL, Mazzara GP, Panicali DL, Herndon JG, Glickman R, Candido MA, Lydy SL, Wyand MS, McClure HM.

Nat Med. 1999 May;5(5):526-34.

PMID:
10229229
35.

Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer.

Sanda MG, Smith DC, Charles LG, Hwang C, Pienta KJ, Schlom J, Milenic D, Panicali D, Montie JE.

Urology. 1999 Feb;53(2):260-6.

PMID:
9933036
36.

Inhibition of allergic encephalomyelitis in marmosets by vaccination with recombinant vaccinia virus encoding for myelin basic protein.

Genain CP, Gritz L, Joshi N, Panicali D, Davis RL, Whitaker JN, Letvin NL, Hauser SL.

J Neuroimmunol. 1997 Nov;79(2):119-28.

PMID:
9394784
37.

Gene gun-based nucleic acid immunization alone or in combination with recombinant vaccinia vectors suppresses virus burden in rhesus macaques challenged with a heterologous SIV.

Fuller DH, Simpson L, Cole KS, Clements JE, Panicali DL, Montelaro RC, Murphey-Corb M, Haynes JR.

Immunol Cell Biol. 1997 Aug;75(4):389-96.

PMID:
9315483
38.

Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T cell loss: evidence supporting a protective role for CTL in vivo.

Greenough TC, Brettler DB, Somasundaran M, Panicali DL, Sullivan JL.

J Infect Dis. 1997 Jul;176(1):118-25.

PMID:
9207357
39.

Early HIV-1 envelope-specific cytotoxic T lymphocyte responses in vertically infected infants.

Pikora CA, Sullivan JL, Panicali D, Luzuriaga K.

J Exp Med. 1997 Apr 7;185(7):1153-61.

40.

Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer.

Schlom J, Kantor J, Abrams S, Tsang KY, Panicali D, Hamilton JM.

Breast Cancer Res Treat. 1996;38(1):27-39. Review.

PMID:
8825120
41.

A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate.

Hodge JW, Schlom J, Donohue SJ, Tomaszewski JE, Wheeler CW, Levine BS, Gritz L, Panicali D, Kantor JA.

Int J Cancer. 1995 Oct 9;63(2):231-7.

PMID:
7591210
42.
43.

Virus burden in long-term survivors of human immunodeficiency virus (HIV) infection is a determinant of anti-HIV CD8+ lymphocyte activity.

Ferbas J, Kaplan AH, Hausner MA, Hultin LE, Matud JL, Liu Z, Panicali DL, Nerng-Ho H, Detels R, Giorgi JV.

J Infect Dis. 1995 Aug;172(2):329-39.

PMID:
7622874
44.

Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.

Wang M, Bronte V, Chen PW, Gritz L, Panicali D, Rosenberg SA, Restifo NP.

J Immunol. 1995 May 1;154(9):4685-92.

45.

HIV-1-specific cytotoxic T lymphocyte responses in the first year of life.

Luzuriaga K, Holmes D, Hereema A, Wong J, Panicali DL, Sullivan JL.

J Immunol. 1995 Jan 1;154(1):433-43.

PMID:
7995957
46.

Induction of antigen-specific killer T lymphocyte responses using subunit SIVmac251 gag and env vaccines containing QS-21 saponin adjuvant.

Newman MJ, Munroe KJ, Anderson CA, Murphy CI, Panicali DL, Seals JR, Wu JY, Wyand MS, Kensil CR.

AIDS Res Hum Retroviruses. 1994 Jul;10(7):853-61.

PMID:
7986590
47.

High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection.

Daniel MD, Mazzara GP, Simon MA, Sehgal PK, Kodama T, Panicali DL, Desrosiers RC.

AIDS Res Hum Retroviruses. 1994 Jul;10(7):839-51.

PMID:
7986589
48.

Analysis of cytotoxic T lymphocyte responses to SIV proteins in SIV-infected macaques using antigen-specific stimulation with recombinant vaccinia and fowl poxviruses.

Kent SJ, Stallard V, Corey L, Hu SL, Morton WR, Gritz L, Panicali DL, Greenberg PD.

AIDS Res Hum Retroviruses. 1994 May;10(5):551-60.

PMID:
7917517
49.

Normal immune function and inability to isolate virus in culture in an individual with long-term human immunodeficiency virus type 1 infection.

Greenough TC, Somasundaran M, Brettler DB, Hesselton RM, Alimenti A, Kirchhoff F, Panicali D, Sullivan JL.

AIDS Res Hum Retroviruses. 1994 Apr;10(4):395-403.

PMID:
8068417
50.

Immunization with lentivirus-like particles elicits a potent SIV-specific recall cytotoxic T-lymphocyte response in rhesus monkeys.

Shen L, Mazzara GP, DiSciullo SO, Panicali DL, Letvin NL.

AIDS Res Hum Retroviruses. 1993 Feb;9(2):129-32.

PMID:
8384466

Supplemental Content

Loading ...
Support Center